Early trial results of a newly developed drug for advanced prostate cancer have been described by medical experts as “remarkable,” raising hopes for patients who have exhausted conventional treatment options.
The innovative therapy is a form of immunotherapy designed to activate the body’s own immune system against cancer.
According to researchers, the treatment not only helped shrink existing tumors but also demonstrated the ability to halt further tumor growth.
Cancer specialists have welcomed the findings, particularly because traditional immunotherapies have historically shown limited success in prostate cancer.
In many cases, earlier treatments failed to significantly reduce tumors and were associated with severe side effects.
However, the new drug, VIR-5500, uses a unique “stealth activation” mechanism. This system ensures the drug remains inactive while circulating in the body and only becomes active once it reaches the tumor site, significantly lowering the risk of harmful side effects.
The results were presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium.
Researchers reported that the drug was tested on 58 men with advanced-stage prostate cancer whose disease had stopped responding to other treatments.
Experts caution that while the early findings are promising, larger clinical trials will be required to confirm the drug’s safety and long-term effectiveness before it becomes widely available.
